Adrenocortical cancer: Single center experience
Abstract
Aim: Adrenocortical cancer is a rare type of disease. Prognosis is poor despite cytotoxic chemotherapies. The primary treatment is surgery however postoperative disease relapse is common. The survival is poorer in patients who develop recurrence. Adjuvan treatment may be performed in patients carrying high risk. Cytotoxic chemotherapy is the only treatment option for inoperable and metastatic patients. In our study, we aimed to evaluate our patient outcome in this rarely seen cancer type. Materials and Methods: We retrospectively reviewed medical records of patients with adrenocortical cancer admitted to Ege University Medical Oncology Clinic between 2010 and 2018. Patient demographics, treatment types for adjuvant and metastatic setting and survival data were collected. Results: We identified 11 adrenocortical cancer patients. Median age was 44 (31-69). Three patients were metastatic at initial diagnosis. Five of 8 patients with nonmetastatic disease received adjuvant chemotherapy . The median overall survival (OS) was 30.2 months (%95 CI 7.9-52.4) in whole patient group. The median OS was found to be better in patients who presented with local disease than de novo metastatic setting (median OS 48.5 and 11.3 months respectively, p=0.02). The OS was 48.5 and 9 months respectively in patients who did and did not receive adjuvant treatment, however this finding was not found to be statistically significant. Conclusion: Nonmetastatic adrenocortical tumor patients who received adjuvant chemotherapy was found to have a slightly favorable OS. However present findings may not enlighten the management of this disease without evaluating treatment efficacy of these patients on multicenter, prospective trial study results.
Keywords
Kaynakça
- Ng L, Libertino JM. Adrenocortical carcinoma: Diagnosis, evaluation and treatment. J Urol 2003;169(1):5-11.
- Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: Analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996;119(2):161-70.
- Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002;87(12):5367-84.
- Schultz CL, Haaga JR, Fletcher BD, Alfidi RJ, Schultz MA. Magnetic resonance imaging of the adrenal glands: A comparison with computed tomography. Am J Roentgenol 1984;143(6):1235-40.
- Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol 2004;5(12):718-26.
- Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010;57(5):873-8.
- Dickstein G, Shechner C, Arad E, Best LA, Nativ O. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998;83(9):3100-3.
- Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993;71(10):3119-23.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
14 Mart 2019
Gönderilme Tarihi
5 Aralık 2018
Kabul Tarihi
14 Ocak 2019
Yayımlandığı Sayı
Yıl 2019 Cilt: 58 Sayı: 1